How it works:
Sofosbuvir inhibits the HCV NS5B RNA-dependent polymerase
Velpatasvir blocks the NS5A protein involved in viral replication
The combination suppresses viral replication across all genotypes
Effective in treatment-naïve and cirrhotic patients
Recommended for:
Adults with chronic hepatitis C
Patients with any HCV genotype
Those who have not received prior therapy
Patients with compensated liver cirrhosis
Use under supervision of a specialist in infectious diseases or hepatology
VELASOF is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults regardless of genotype.
Take one tablet orally once daily, with or without food. The usual treatment duration is 12 weeks, as directed by a healthcare professional.
Contraindications:
Hypersensitivity to any component
Severe renal impairment
Under 18 years of age
Concurrent use of drugs that significantly reduce drug levels
Side effects:
Headache
Fatigue
Nausea
Insomnia
Anaemia (rare)
Elevated liver enzymes
